13.06.2015 16:01:36
|
AstraZeneca Records Reduced Serum Uric Acid Levels In Phase III Crystal Study
(RTTNews) - AstraZeneca Plc (AZN.L) Saturday announced positive results for its phase III Crystal study of lesinurad, a selective uric acid re-absorption inhibitor in combination with xanthine oxidase inhibitor (XOI) febuxostat. The combination reduced the serum uric acid levels and reduced tophus area to a greater extent than febuxostat alone. It increases excretion and decreases production of uric acid. The goal the urate lowering treatment was to reduce serum uric acid levels to the recommended treatment targets.
In the trial, patients were administered febuxostat 80 mg orally once daily for 3 weeks before randomisation to the combination treatments. Further, the company said the lesinurad in combination with febuxostat did not result in a significant difference in the proportion of subjects achieving a complete resolution of at least one tophus by month 12. However, lesinurad combination treatment with both 200mg and 400mg did result in greater total tophus area reduction at month 12 compared to febuxostat alone.
Johan Hoegstedt, Global Medicines Leader for lesinurad said, "While no oral agent has demonstrated a beneficial effect on flares in 12-month randomized controlled clinical trials, this analysis showed that over time - as lower sUA levels were maintained - flares decrease and tophus area reduced."

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AstraZeneca PLC (spons. ADRs)mehr Nachrichten
17.03.25 |
Gewinne in New York: NASDAQ 100 mit Kursplus (finanzen.at) | |
17.03.25 |
Börse New York: NASDAQ 100 sackt am Mittag ab (finanzen.at) | |
17.03.25 |
AstraZeneca-Aktie im Minus: Zelltherapie-Portfolio verstärkt (Dow Jones) | |
17.03.25 |
Schwacher Handel in New York: NASDAQ 100 beginnt Handel im Minus (finanzen.at) | |
14.03.25 |
Zuversicht in New York: NASDAQ 100 zum Ende des Freitagshandels im Plus (finanzen.at) | |
14.03.25 |
Aufschläge in New York: NASDAQ 100 zeigt sich am Freitagnachmittag fester (finanzen.at) | |
14.03.25 |
Aufschläge in New York: NASDAQ 100 am Freitagmittag stärker (finanzen.at) | |
14.03.25 |
NASDAQ-Handel: NASDAQ 100 verbucht zum Start des Freitagshandels Zuschläge (finanzen.at) |
Analysen zu AstraZeneca PLC (spons. ADRs)mehr Analysen
Aktien in diesem Artikel
AstraZeneca PLC (spons. ADRs) | 70,50 | 0,00% |
|